Recent literature suggests that prognostic factors for adverse outcomes after AKI (such as proteinuria) [15] and risk-benefit ratio of renin-angiotensin system blockade therapy after AKI [9, 10, 13, 14] are actually similar to those seen in other high-risk patients who have been hospitalized and either have or are at high risk for having chronic kidney disease (CKD). The gene discussed is REN; the disease is chronic kidney disease.